文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病患者肠道微生物群的持久改变

Lasting shift in the gut microbiota in patients with acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

本研究对52例急性髓系白血病(AML)患者的410份纵向粪便样本进行肠道微生物群测序,发现住院化疗期间肠道微生物群受到超出其恢复原始状态能力的应激,出院后尽管抗生素压力和其他干扰大幅减少,微生物群恢复轨迹仍形成与基线高度不同的新群落,这种持久改变与后续治愈性治疗阶段相关,并可能是新型微生物群保护/恢复干预的潜在靶点。

要点

  • 住院化疗期间AML患者肠道微生物群受到超出恢复能力的应激。
  • 出院后抗生素压力等干扰减少,但微生物群恢复为与基线高度不同的新群落。
  • 该持久改变与后续治愈性治疗阶段相关,并可能是微生物群保护/恢复干预的靶点。

核心结论

  • AML患者住院化疗期间肠道微生物群受到超出其恢复原始状态能力的应激,出院后仍形成与基线高度不同的新群落,呈现持久改变。
  • 这种持久改变与后续治愈性治疗阶段相关,并可能是新型微生物群保护/恢复干预的潜在靶点。

研究设计与样本

  • 对52例AML患者的410份纵向粪便样本进行肠道微生物群测序。
  • 试验注册号为NCT03316456。

主要发现

  • 住院化疗期间肠道微生物群受到超出其恢复原始状态能力的应激。
  • 出院后抗生素压力和其他干扰大幅减少,但微生物群恢复轨迹仍形成与基线高度不同的新群落。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous studies have shown that the gut microbiota of patients with acute myeloid leukemia (AML) is disrupted during induction chemotherapy; however, the durability of microbiota changes is unknown. This is an important knowledge gap, because reduced microbiota diversity at the time of stem cell transplantation weeks to months after the initial chemotherapy has been associated with higher mortality after transplantation. By sequencing the gut microbiota in 410 longitudinal stool samples from 52 patients with AML, we found that, during inpatient chemotherapy, the gut microbiota is stressed beyond its ability to recover its original state. Despite major reductions in antibiotic pressure and other disturbances to the microbiota after hospital discharge, the trajectory of microbiota recovery yields new communities that are highly dissimilar to baseline. This lasting shift in the gut microbiota is relevant for subsequent phases of curative therapy and is a potential target for novel microbiota protective/restorative interventions. This trial was registered at www.clinicaltrials.gov as #NCT03316456.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rashidi A, Ebadi M, Rehman TU, et al. Lasting shift in the gut microbiota in patients with acute myeloid leukemia. Blood Adv. 2022. PMID: 35192686. doi:10.1182/bloodadvances.2021006783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。